Emergent BioSolutions
EBS
5,42 €
Share price
0.47%
Change (1 day)
-17.58%
Change (1 year)
Categories
Emergent BioSolutions (EBS) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : €0.74 Billion
According to Emergent BioSolutions 's latest financial reports the company's total liabilities are €0.74 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Emergent BioSolutions - Total liabilities on balance sheet (from 2004 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | €0.87 B | -17.93% |
| 2023-12-31 | €1.06 B | -35.96% |
| 2022-12-31 | €1.65 B | 39.49% |
| 2021-12-31 | €1.18 B | 1.8% |
| 2020-12-31 | €1.16 B | 5.59% |
| 2019-12-31 | €1.10 B | 3.82% |
| 2018-12-31 | €1.06 B | 709.37% |
| 2017-12-31 | €0.13 B | -62.98% |
| 2016-12-31 | €0.35 B | 2.97% |
| 2015-12-31 | €0.34 B | 8.92% |
| 2014-12-31 | €0.31 B | 218.43% |
| 2013-12-31 | €99.53 M | 7.83% |
| 2012-12-31 | €92.3 M | -7.88% |
| 2011-12-31 | €0.10 B | 5.15% |
| 2010-12-31 | €95.29 M | 35.35% |
| 2009-12-31 | €70.4 M | 7.65% |
| 2008-12-31 | €65.4 M | -6.69% |
| 2007-12-31 | €70.09 M | -7.31% |
| 2006-12-31 | €75.62 M | 120.67% |
| 2005-12-31 | €34.26 M | 0.82% |
| 2004-12-31 | €33.98 M | |
| 2002-12-31 | €17.82 M | -72.72% |
| 2001-12-31 | €65.35 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Merck MRK | €56.68 B | 7,539.34% | 🇺🇸 USA |
 SIGA Technologies SIGA | €26.28 M | -96.46% | 🇺🇸 USA |
 GlaxoSmithKline GSK | €51.65 B | 6,860.63% | 🇬🇧 UK |
 Celldex Therapeutics CLDX | €31 M | -95.82% | 🇺🇸 USA |
 Pfizer PFE | €99.73 B | 13,340.69% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | €27.31 B | 3,580.56% | 🇮🇱 Israel |
 Soligenix SNGX | €3.51 M | -99.53% | 🇺🇸 USA |